Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Exclusion Criteria

• •Current diagnosis with another chronic kidney disease, including diabetic kidney disease.
• •History of kidney transplantation or other organ transplantation.
• •Use of systemic immunosuppressant medications, such as steroids, for more than 2 weeks in the past 3 months.
• •Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the Investigator.
• •Known history of heart failure or prior hospital admissions for conditions relating to fluid overload that in the opinion of the Principal Investigator or Sponsor might confound the results of the study or pose additional risk to the participant by their participation in the study.
• •Clinically significant history of liver disease as assessed by the Investigator.
• •Hemoglobin below 9 g/dL as measured by the Investigator or prior history of blood transfusion for anemia within the past 3 months.
• •Malignancy within the past 5 years. Exceptions to this criteria include nonmelanoma skin cancer and curatively treated cervical carcinoma in situ.
• •For women, pregnancy, breast feeding, or intent to become pregnant during the study. and at least 1 month afterward.
• •For men, intent to father a child or donate sperm during the study.
• •Have received any investigational agent or approved treatment for IgAN (other than a RAS inhibitor) including SGLT2i (except for subjects in the SGLT2i stable stratum) within 1 month (or 5 half-lives of the agent, whichever is longer) prior to Screening. If the investigational agent is a cytotoxic or immunosuppressive agent then this washout period is 6 months.